Q Therapeutics’ and Invitrogen’s Symbiotic Relationship

Posted on February 25, 2008 by jrowley

Q Therapeutics, a cell therapy company focusing on neural applications, recently announced a $15M series B financing that included funding from multiple venture capital (VC) groups as well as biotech tools provider Invitrogen. Q’s lead product, Q-Cells™, is an allogeneic product intended to restore function to damaged neurons by providing trophic (e.g. cytokines, growth factors) [...]

Filed under: adult stem cell, Bioprocessing, Clinical Trials, Company Profiles, Manufacturing, MS, Neural Repair, Q Therapeutics, Regenerative Medicine, stem cells | Tagged: , , , | 2 Comments »

New Vascular Closure Devices Aim to Gain Bigger Piece of Endovascular Device Market

Posted on February 24, 2008 by shsiong

by Susan Hsiong, PhD More than 12 million minimally invasive vascular surgeries are done every year. These procedures require catheterization of major blood vessels to gain access to the vasculature. While catheter technology has dramatically improved, closure of the vessel puncture wound post surgery remaines a challenge. Manual compression of the puncture site is the [...]

Filed under: AccessClosure, biomaterial devices, Biomaterials, Datascope, NeoMend, PEG-based Biomaterials, St. Jude Medical, Vascular Closure, vascular regeneration | Tagged: , , , , , , , | Leave a Comment »

The Developing Embyronic Stem Cell Clinical Landscape

Posted on February 14, 2008 by jrowley

ES cell biopsy from blastocyst.

Filed under: adult stem cell, Advanced Cell Technology, Athersys, Clinical Trials, Cytori, Embyonic Stem Cells, FDA, Geron, JNJ, Novocell, Osiris, Regenerative Medicine, spinal cord injury, stem cells | Tagged: , , , , | Leave a Comment »

Geron Bolsters Extensive Embryonic Stem Cell Patent Estate

Posted on February 7, 2008 by jrowley

Geron yesterday announced the issuance of US patent #7,326,572, helping to extend their patent protection around their embryonic stem (ES) cell platform technology in the area of treating type 1 diabetes. Currently, Geron owns an exclusive license from the Wisconsin Alumni Research Foundation (WARF) for James Tomson’s original ES patents. This license allows Geron the [...]

Filed under: Embyonic Stem Cells, Geron, Intellectual Property, Novocell, Regenerative Medicine, Type 1 diabetes | Tagged: , , , | Leave a Comment »

Career Strategy Tip: Read Job Posts, Even if You are Not Graduating for 2-3 Years

Posted on February 5, 2008 by jrowley

I always found it extremely useful to read and monitor job posts, even well before I had any reason to send out my resume. Reading about various jobs give you an understanding of 1) what jobs are out there that you might be interested in, and more importantly 2) what gaps you have in your [...]

Filed under: Job search, Regenerative Medicine | Tagged: , , | 1 Comment »

Cytori Announces Progress in Cardiac Regeneration Clinical Studies

Posted on February 1, 2008 by jrowley

Cytori Therapeutics announced that they have enrolled their first two patients in an acute myocardial infarction clinical trial using adipose-derived cells prepared using their Celution™ device. The Celution™ device is an automated, tissue processing unit that isolates cells from adipose tissue derived via liposuction.

Filed under: adult stem cell, autologous, Bioprocessing, cardiac regeneration, cell delivery, Clinical Trials, Company Profiles, Cytori, Device-centric cell therapies, patient specific cell therapy, personalized medicine, Regenerative Medicine, stem cells | Leave a Comment »

  • Subscribe via email

    Subscribe to The Regeneration Station by Email

  • Top Posts

  • a

Follow

Get every new post delivered to your Inbox.